장 질환 검사 시장 - 세계 예측(2026-2032년)

The Enteric Disease Testing Market is projected to grow by USD 7.00 billion at a CAGR of 5.41% by 2032.

Enteric disease testing is becoming a critical pillar of infectious disease surveillance, clinical diagnostics, food safety, antimicrobial stewardship, and outbreak response. Enteric infections caused by bacteria, viruses, and parasites remain a major public health burden, with the World Health Organization reporting that unsafe food causes hundreds of millions of illnesses annually and that diarrheal diseases continue to disproportionately affect children, older adults, immunocompromised populations, travelers, and communities with limited water and sanitation infrastructure. In this environment, laboratories, hospitals, public health agencies, food producers, and environmental monitoring programs are prioritizing faster, more accurate, and more scalable diagnostic approaches.

The testing landscape spans stool culture, microscopy, immunoassays, syndromic molecular panels, polymerase chain reaction testing, sequencing-based pathogen characterization, and metagenomic approaches. Demand is shaped by rising recognition of foodborne outbreaks, increasing international travel, climate-linked pathogen distribution changes, improved surveillance mandates, and the need to distinguish bacterial, viral, and parasitic causes of gastrointestinal illness. Themes defining this sector include enteric disease diagnostics, gastrointestinal infection testing, stool pathogen testing, foodborne pathogen detection, multiplex PCR gastrointestinal panels, antimicrobial resistance surveillance, and public health outbreak testing.

Transformative Shifts in the Enteric Disease Testing Landscape

The enteric disease testing landscape is shifting from slow, pathogen-by-pathogen workflows toward integrated, syndromic, and surveillance-ready diagnostic systems. Traditional culture remains essential for isolate recovery, antimicrobial susceptibility testing, and epidemiological investigations, but molecular diagnostics are increasingly used to support rapid clinical decision-making. Multiplex gastrointestinal panels can detect common bacterial, viral, and parasitic pathogens from a single specimen, helping clinicians shorten diagnostic uncertainty and public health teams identify clusters more quickly.

A second transformative shift is the convergence of clinical diagnostics with food safety and environmental surveillance. Whole-genome sequencing and genomic epidemiology are strengthening the ability to link patient isolates with contaminated foods, water sources, animal reservoirs, or production environments. Public health laboratories are also expanding digital data exchange to improve cross-border outbreak detection. At the same time, antimicrobial resistance is influencing testing strategies, as resistant strains of Salmonella, Shigella, Campylobacter, and other enteric pathogens require more precise monitoring.

Operationally, laboratories are emphasizing automation, sample-to-answer platforms, quality-assured workflows, and test stewardship. Because broad molecular panels may identify colonization, prolonged shedding, or organisms of uncertain clinical relevance, interpretation now requires stronger coordination between clinicians, microbiologists, epidemiologists, and infection prevention teams. The sector's direction is therefore defined not only by faster testing but by smarter testing that connects diagnostics to treatment, surveillance, and prevention.

Cumulative Impact of Artificial Intelligence on Enteric Disease Testing

Artificial intelligence is beginning to reshape enteric disease testing across laboratory operations, epidemiological surveillance, pathogen genomics, and decision support. In diagnostic laboratories, AI-enabled workflow tools can support specimen routing, quality control monitoring, result pattern recognition, and automated flagging of unusual pathogen combinations or positivity trends. These capabilities are especially relevant for high-volume stool pathogen testing programs, where turnaround time and interpretive consistency directly affect patient management and outbreak response.

In public health surveillance, AI and machine learning can analyze laboratory results alongside emergency department visits, pharmacy data, food safety alerts, climate variables, wastewater indicators, and mobility patterns to detect anomalies earlier than manual review alone. Genomic epidemiology is another high-impact application: machine learning can assist with sequence classification, cluster detection, resistance marker interpretation, and comparison of isolates across regional or national databases. These tools are particularly valuable when investigating dispersed foodborne outbreaks that may involve low case numbers across multiple jurisdictions.

The cumulative impact of AI, however, depends on data quality, interoperability, governance, and explainability. Enteric disease testing generates sensitive clinical and epidemiological data, making privacy protection, validation, bias assessment, and human oversight essential. AI is not replacing laboratory expertise; it is augmenting the ability to prioritize samples, interpret complex datasets, accelerate outbreak signals, and support evidence-based public health action.

Key Regional Insights for Enteric Disease Testing

Asia-Pacific is a high-priority region for enteric disease testing because of its large population base, dense urban centers, diverse food supply chains, monsoon-related flooding risks, and uneven access to safe water and sanitation across countries. Surveillance programs in the region increasingly focus on diarrheal disease burden, cholera risk, typhoid fever, foodborne bacterial pathogens, and antimicrobial resistance, while advanced economies are adopting molecular gastrointestinal panels and sequencing to strengthen outbreak investigations.

Europe has a highly coordinated surveillance environment, with emphasis on cross-border foodborne outbreak detection, antimicrobial resistance monitoring, and harmonized quality standards. Regional laboratories increasingly combine culture, molecular testing, and sequencing to support both clinical care and public health action. North America demonstrates mature adoption of molecular diagnostics, foodborne outbreak surveillance, laboratory automation, and genomic epidemiology. The region's testing ecosystem is supported by integrated public health reporting, strong clinical laboratory infrastructure, and active monitoring of pathogens such as Salmonella, Shiga toxin-producing Escherichia coli, Campylobacter, Listeria, norovirus, and Clostridioides difficile. Rising attention to antimicrobial-resistant enteric pathogens and decentralized testing models is reinforcing the need for standardized result interpretation and data interoperability.

Latin America faces a dual challenge of persistent diarrheal disease burden and expanding modernization of diagnostic capacity. Urbanization, informal food markets, climate variability, and water infrastructure gaps influence pathogen exposure, while major countries are expanding laboratory networks for food safety, travel-associated infections, and outbreak control. Africa remains closely linked to child health, cholera preparedness, typhoid surveillance, water safety, and laboratory capacity strengthening. Investments in molecular diagnostics, reference laboratory networks, and sample transport systems are improving detection, but access disparities continue to influence testing coverage and timeliness.

The Middle East is shaped by rapid urbanization, international travel, mass gatherings, imported food dependency, and varying water scarcity risks, all of which increase the importance of rapid gastrointestinal pathogen testing and outbreak preparedness. Across all regions, enteric disease diagnostics are increasingly tied to climate resilience, food system monitoring, antimicrobial resistance containment, and real-time public health intelligence.

Key Group Insights for Enteric Disease Testing

NATO member countries overlap significantly with high-income diagnostic systems in North America and Europe, where enteric disease testing is closely tied to force health protection, travel medicine, biosurveillance, and resilient public health infrastructure. G7 countries generally have advanced clinical microbiology networks, high adoption of molecular and sequencing-based tools, and strong outbreak analytics, although test stewardship and data interoperability remain ongoing priorities.

BRICS countries represent a highly diverse testing environment, combining large population health needs with expanding diagnostic infrastructure and public health modernization. China, India, Brazil, Russia, and South Africa face different enteric disease profiles, but shared priorities include food safety, typhoid and cholera preparedness, antimicrobial resistance tracking, and improved access to laboratory-confirmed diagnosis. The European Union benefits from harmonized food safety frameworks, cross-border notification systems, and established genomic surveillance practices, making it a leading group for integrated outbreak detection and antimicrobial resistance monitoring.

ASEAN countries are strengthening enteric disease testing through regional disease surveillance cooperation, food safety modernization, and laboratory capacity expansion. Tropical climates, flood exposure, high population mobility, and diverse food systems make rapid detection of bacterial, viral, and parasitic gastrointestinal pathogens an important public health priority. Molecular diagnostics and reference laboratory networks are gaining relevance as countries work to improve outbreak confirmation and antimicrobial resistance surveillance.

The GCC is advancing enteric disease testing in response to mass gatherings, expatriate workforce mobility, imported food reliance, and water security priorities. Rapid stool pathogen testing, foodborne pathogen detection, and environmental monitoring are increasingly relevant to public health preparedness. For these groups, the strategic value of enteric disease diagnostics extends beyond routine clinical care to include emergency preparedness, food supply security, antimicrobial resistance containment, and cross-border health intelligence.

Key Country Insights for Enteric Disease Testing

China is expanding molecular diagnostics, hospital laboratory automation, food safety testing, and pathogen genomics to address both domestic disease surveillance and complex food supply chains. The United States has a highly developed enteric disease testing environment supported by clinical laboratories, public health surveillance networks, food safety monitoring, and genomic epidemiology. Testing priorities include Salmonella, Shiga toxin-producing Escherichia coli, Campylobacter, norovirus, Listeria, Shigella, and antimicrobial-resistant gastrointestinal pathogens. Japan emphasizes quality-controlled clinical testing, food safety, and aging-population healthcare needs, while India has substantial demand for enteric disease testing due to typhoid burden, diarrheal disease prevalence, antimicrobial resistance concerns, monsoon-related waterborne disease risk, and increasing availability of molecular diagnostics in urban centers.

Germany, the United Kingdom, France, Italy, and Spain maintain advanced laboratory systems that integrate clinical microbiology, molecular diagnostics, food safety testing, and public health reporting. Germany and France have strong reference laboratory capabilities, while the United Kingdom emphasizes genomic surveillance and coordinated outbreak analytics. Italy and Spain continue to advance molecular gastrointestinal testing alongside established culture-based workflows. Australia combines strong public health surveillance, outbreak response, and regional reference laboratory capacity, particularly for foodborne and travel-associated infections. South Korea has advanced hospital laboratory infrastructure and rapid adoption of molecular infectious disease testing, supporting timely detection of gastrointestinal pathogens and coordinated public health response.

Canada emphasizes foodborne illness surveillance, laboratory quality systems, and regional coordination across provinces, with molecular testing and sequencing increasingly supporting outbreak investigations. Russia's enteric disease testing landscape reflects broad geographic scale, food safety needs, and surveillance priorities for bacterial and viral gastrointestinal infections. Brazil and Mexico are important Latin American settings for enteric disease diagnostics due to large populations, urban food systems, travel-related infection risks, and ongoing public health needs related to diarrheal disease and waterborne pathogens. Brazil's surveillance priorities include bacterial enteric pathogens, parasitic infections, and food safety monitoring, while Mexico's testing demand is influenced by clinical diagnostics, tourism, cross-border mobility, and foodborne outbreak preparedness.

Actionable Recommendations for Enteric Disease Testing Leaders

Industry leaders should prioritize diagnostic strategies that balance speed, clinical relevance, surveillance value, and cost-effective implementation. Molecular gastrointestinal panels should be deployed with clear testing criteria, interpretive guidance, and reflex culture or sequencing pathways when isolate recovery, antimicrobial susceptibility testing, or outbreak confirmation is required. Laboratories should preserve culture capacity where it remains essential for public health investigations and resistance monitoring.

Organizations should invest in interoperability between laboratory information systems, hospital records, public health reporting platforms, and genomic surveillance databases. Faster reporting is most valuable when results can be translated into treatment decisions, infection control measures, and outbreak alerts. Leaders should also strengthen antimicrobial resistance surveillance by integrating phenotypic susceptibility testing, molecular resistance markers, and epidemiological metadata.

Operationally, the highest-impact actions include standardizing stool specimen collection and transport, validating assays across diverse pathogen targets, training clinicians on result interpretation, establishing test stewardship committees, and improving turnaround time for high-risk patient groups. Food safety and environmental testing programs should align laboratory workflows with hazard analysis, traceability, and regulatory reporting requirements. Finally, AI-enabled analytics should be adopted cautiously through validated use cases, transparent governance, and human-in-the-loop review to ensure reliable, ethical, and actionable insights.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified, evidence-based sources relevant to enteric disease testing. The approach includes review of public health guidance, peer-reviewed infectious disease literature, laboratory standards, food safety surveillance publications, antimicrobial resistance reports, genomic epidemiology resources, and regional disease surveillance documentation. Emphasis is placed on information from recognized health authorities, scientific journals, regulatory bodies, and laboratory medicine organizations.

The research framework evaluates diagnostic modalities, pathogen priorities, clinical utility, laboratory workflow requirements, regional surveillance capacity, outbreak response practices, and emerging technology adoption. Insights are triangulated across multiple source categories to reduce bias and ensure consistency. Particular attention is given to differentiating clinical testing from public health testing, food safety testing, and environmental surveillance, as each setting has distinct performance requirements and decision-making implications.

No market sizing, market share estimation, or forecasting assumptions are used. The analysis focuses on qualitative and evidence-backed dynamics, including technology adoption patterns, disease burden drivers, policy relevance, operational challenges, and strategic opportunities for stakeholders in enteric disease diagnostics.

Conclusion

Enteric disease testing is evolving into an integrated diagnostic and surveillance discipline that connects patient care, food safety, antimicrobial resistance monitoring, and outbreak preparedness. The shift from conventional pathogen detection toward multiplex molecular testing, sequencing, digital reporting, and AI-assisted analytics is improving the speed and precision of gastrointestinal infection diagnosis. However, effective implementation requires careful test stewardship, culture and sequencing support, interoperable data systems, and strong collaboration between clinical, public health, and food safety stakeholders.

Regional and country-level differences remain significant, shaped by disease burden, laboratory infrastructure, regulatory systems, water and sanitation conditions, food supply complexity, and public health investment. The most resilient testing strategies will combine rapid detection with actionable interpretation, enabling faster treatment decisions, targeted interventions, and stronger surveillance. As enteric pathogens continue to adapt through antimicrobial resistance, climate-linked distribution changes, and globalized food networks, enteric disease testing will remain central to protecting population health and strengthening infectious disease preparedness.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Enteric Disease Testing Market, by Test Method

• 7.1. Introduction
• 7.2. Biochemical Tests
  • 7.2.1. Automated Biochemical Analysis
  • 7.2.2. Manual Biochemical Tests
• 7.3. Culture Methods
  • 7.3.1. Non Selective Culture
  • 7.3.2. Selective Culture
• 7.4. Immunoassays
  • 7.4.1. Chemiluminescence Immunoassay
  • 7.4.2. Enzyme Linked Immunosorbent Assay
  • 7.4.3. Lateral Flow Assay
• 7.5. Molecular Diagnostics
  • 7.5.1. Loop Mediated Isothermal Amplification
  • 7.5.2. Polymerase Chain Reaction
  • 7.5.3. Real Time Polymerase Chain Reaction
• 7.6. Sequencing
  • 7.6.1. Next Generation Sequencing
  • 7.6.2. Sanger Sequencing

8. Enteric Disease Testing Market, by Product Type

• 8.1. Introduction
• 8.2. Consumables
  • 8.2.1. Kits
  • 8.2.2. Reagents
• 8.3. Instruments
  • 8.3.1. Immuno Analyzers
  • 8.3.2. Polymerase Chain Reaction Instruments
  • 8.3.3. Sequencers
• 8.4. Software & Services
  • 8.4.1. Data Analysis Software
  • 8.4.2. Maintenance Services

9. Enteric Disease Testing Market, by Pathogen

• 9.1. Introduction
• 9.2. Bacterial Pathogens
  • 9.2.1. Campylobacter
  • 9.2.2. Escherichia Coli
  • 9.2.3. Salmonella
• 9.3. Parasitic Pathogens
• 9.4. Viral Pathogens
  • 9.4.1. Adenovirus
  • 9.4.2. Norovirus
  • 9.4.3. Rotavirus

10. Enteric Disease Testing Market, by Sample Type

• 10.1. Introduction
• 10.2. Blood Samples
• 10.3. Rectal Swabs
• 10.4. Stool Samples

11. Enteric Disease Testing Market, by End User

• 11.1. Introduction
• 11.2. Academic And Clinical Laboratories
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals
• 11.5. Research Institutes

12. Enteric Disease Testing Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Direct Sales
• 12.3. Distributors
• 12.4. Online Sales

13. Enteric Disease Testing Market, by Region

• 13.1. Asia-Pacific
• 13.2. Europe
• 13.3. North America
• 13.4. Latin America
• 13.5. Africa
• 13.6. Middle East

14. Enteric Disease Testing Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. BRICS
• 14.4. European Union
• 14.5. ASEAN
• 14.6. GCC

15. Enteric Disease Testing Market, by Country

• 15.1. China
• 15.2. United States
• 15.3. Japan
• 15.4. India
• 15.5. Germany
• 15.6. United Kingdom
• 15.7. Australia
• 15.8. France
• 15.9. South Korea
• 15.10. Italy
• 15.11. Canada
• 15.12. Russia
• 15.13. Brazil
• 15.14. Mexico
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. 3M Company
• 17.2. Abbott Laboratories
• 17.3. Als Limited
• 17.4. Asure Quality
• 17.5. Becton, Dickinson and Company
• 17.6. Bio-Rad Laboratories, Inc.
• 17.7. Biomerica Inc.
• 17.8. bioMerieux SA
• 17.9. Bureau Veritas Group
• 17.10. Cepheid Inc.
• 17.11. Coris BioConcept SPRL
• 17.12. Eurofins Scientific SE
• 17.13. Hardy Diagnostics
• 17.14. Intertek Group PLC
• 17.15. Meridian Bioscience Inc.
• 17.16. Merieux NutriSciences Corporation
• 17.17. Neogen Corporation
• 17.18. Nova Biologicals
• 17.19. Perkinelmer, Inc.
• 17.20. Qiagen N.V.
• 17.21. Quest Diagnostics
• 17.22. Romer Labs Division Holding GmbH
• 17.23. SGS SA
• 17.24. Symbio Laboratories
• 17.25. Thermo Fisher Scientific Inc.
• 17.26. Trinity Biotech PLC
• 17.27. TUV SUD AG